GENB (Generate Biomedicines) Research & Development: $ Mil (TTM As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines Research & Development?

Generate Biomedicines GENB +2.18% 6 Research & Development is $ Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Generate Biomedicines's Research & Development for the six months ended in Dec. 2025 was $224.70 Mil. Generate Biomedicines does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Dec. 2025.

Generate Biomedicines  (NAS:GENB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Generate Biomedicines Research & Development Related Terms

Generate Biomedicines Research & Development Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Research & Development Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Research & Development
175.31 224.70

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Research & Development 175.31 224.70
GENB
6GF Score
Generate Biomedicines Inc GENB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $ Mil mean?
Generate Biomedicines (GENB) has a Research & Development of $ Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Generate Biomedicines and its competitors.
Is Generate Biomedicines' Research & Development too high?
Generate Biomedicines' current Research & Development is $ Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Research & Development compare to PVLA and SLBT?
Generate Biomedicines' Research & Development of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current Research & Development is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Research & Development of $ Mil. The current Research & Development is $ Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Research & Development is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price